July 29, 2019
Nearly a year after its first-of-a-kind approval and ensuing debates surrounding its pricing, the so-called “biosame” version of Kyowa Kirin’s flagship renal anemia drug Nesp (darbepoetin alfa) will finally arrive on the Japanese market on August 5. “We developed this...read more